or Try an Advanced Search...

    Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.66 -3.10% -0.02
    CTXR closed down 3.1 percent on Wednesday, May 8, 2024, on 1.7 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 10
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CTXR trend table...
    Date Alert Name Type % Chg
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Down 3 Days in a Row Weakness -3.10%
    Down 4 Days in a Row Weakness -3.10%
    Down 5 Days in a Row Weakness -3.10%
    Oversold Stochastic Weakness -3.10%
    Outside Day Range Expansion -4.93%
    Older End-of-Day Signals for CTXR ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 13 hours ago
    3x Volume Pace about 13 hours ago
    Down 5% about 13 hours ago
    Fell Below Lower Bollinger Band about 13 hours ago
    Lower Bollinger Band Support about 13 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CTXR Chart by TradingView
    Basic chart:

    Profile

    Citius Pharmaceuticals, Inc. Description

    Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine

    Is CTXR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
    Apr 26 Citius Pharmaceuticals to raise $15M through direct offering; shares fall
    Apr 26 Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
    Apr 11 Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
    Apr 4 Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
    Mar 18 Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment
    Mar 18 Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Mar 12 Sidoti Events, LLC's Virtual March Small-Cap Conference
    Mar 7 Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
    Feb 26 Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
    See more CTXR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.45
    52 Week Low 0.6
    Average Volume 986,030
    200-Day Moving Average 0.78
    50-Day Moving Average 0.78
    20-Day Moving Average 0.74
    10-Day Moving Average 0.70
    Average True Range 0.07
    RSI (14) 38.27
    ADX 15.19
    +DI 23.65
    -DI 24.38
    Chandelier Exit (Long, 3 ATRs) 0.83
    Chandelier Exit (Short, 3 ATRs) 0.85
    Upper Bollinger Bands 0.83
    Lower Bollinger Band 0.64
    Percent B (%b) 0.11
    BandWidth 25.60
    MACD Line -0.04
    MACD Signal Line -0.03
    MACD Histogram -0.0072
    Fundamentals Value
    Market Cap 105.44 Million
    Num Shares 159 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -3.02
    Price-to-Sales 0.00
    Price-to-Book 1.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.75
    Resistance 3 (R3) 0.75 0.72 0.73
    Resistance 2 (R2) 0.72 0.70 0.72 0.73
    Resistance 1 (R1) 0.69 0.69 0.68 0.69 0.72
    Pivot Point 0.67 0.67 0.66 0.67 0.67
    Support 1 (S1) 0.64 0.65 0.62 0.64 0.60
    Support 2 (S2) 0.61 0.63 0.61 0.60
    Support 3 (S3) 0.58 0.61 0.59
    Support 4 (S4) 0.58